MINYANVILLE ORIGINAL Biogen Idec’s (NASDAQ:BIIB) experimental drug for a rare disease that destroys the brain and spinal cord nerve cells failed in a company study. Biogen says it is ending its research program for the drug dexpramipexole. The medicine was the in the late stages of testing for a treatment of amyotrophic lateral sclerosis or ALS which is also commonly known as Lou Gehrig’s disease. While some Wall Street analysts viewed the drug as a long shot study results were highly anticipated and the failure is a disappointing development for a company that has won over a number of ...